课题基金 / 基金详情

USE OF GNRH IN THE TREATMENT OF PROSTATIC CARCINOMA

USE OF GNRH IN THE TREATMENT OF PROSTATIC CARCINOMA
GNRH 在治疗前列腺癌中的应用
批准号：
3886203
负责人：
RONALD S SWERDLOFF
金额：
$0.0万
依托单位：
LOS ANGELES COUNTY HARBOR-UCLA MED CTR
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3886203
关键词：
drug tolerance endocrinology gonadotropin releasing factor human subject human therapy evaluation neoplasm /cancer remission /regression nutrition nutrition aspect of cancer nutrition related tag peptide hormone analog pharmacology prostate neoplasms

项目摘要

项目成果

RONALD S SWERDLOFF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To assess the safety, clinical efficacy and tolerance of the daily administration of Buserelin (HOE 766) for at least 12 months in treatment of patients with prostatic carcinoma. Assessment will be made sequentially at 3 month intervals including objective signs of remission, endocrine, nutritional and other biochemical evaluations and patient's quality of life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II CLINICAL STUDIES WITH LHRH AGONISTS
OLIGOSPERMIA--CONTROLLED COMPARISON OF TWO ANTI-ESTROGENS
TOLERANCE AND SAFETY OF TRANSDERMAL TESTERONE
OLIGOSPERMIA--CONTROLLED COMPARISON OF TWO ANTI-ESTROGENS
海外基金